KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Novavax (NVAX) Amortization of Deferred Charges (2016 - 2020)

Historic Amortization of Deferred Charges for Novavax (NVAX) over the last 6 years, with Q4 2020 value amounting to $356000.0.

  • Novavax's Amortization of Deferred Charges changed 0.0% to $356000.0 in Q4 2020 from the same period last year, while for Dec 2020 it was $1.4 million, marking a year-over-year change of 0.0%. This contributed to the annual value of $1.4 million for FY2020, which is 0.0% changed from last year.
  • Novavax's Amortization of Deferred Charges amounted to $356000.0 in Q4 2020, which was down 0.0% from $356000.0 recorded in Q3 2020.
  • In the past 5 years, Novavax's Amortization of Deferred Charges registered a high of $357000.0 during Q4 2017, and its lowest value of $237000.0 during Q1 2016.
  • In the last 5 years, Novavax's Amortization of Deferred Charges had a median value of $356000.0 in 2016 and averaged $350100.0.
  • As far as peak fluctuations go, Novavax's Amortization of Deferred Charges soared by 5021.1% in 2017, and later decreased by 28.01% in 2018.
  • Over the past 5 years, Novavax's Amortization of Deferred Charges (Quarter) stood at $356000.0 in 2016, then increased by 0.28% to $357000.0 in 2017, then dropped by 0.28% to $356000.0 in 2018, then changed by 0.0% to $356000.0 in 2019, then changed by 0.0% to $356000.0 in 2020.
  • Its Amortization of Deferred Charges stands at $356000.0 for Q4 2020, versus $356000.0 for Q3 2020 and $356000.0 for Q2 2020.